CHMP February 2026 Approvals: New Breakthroughs...

By HEOR Staff Writer

March 3, 2026

CHMP February 2026 Approvals: 12 New Medicines and Biosimilars Advance The
EMA’s mCombriax Vaccine Recommendation
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in A...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...